
New Delhi, 13 July 2021
As per news report of NDTV, "As part of the technical transfer process, SII has already received cell and vector samples from the Gamaleya Center. With their import approved by the Drug Controller General of India), the cultivation process has begun," read a statement from RDIF. "I am delighted to partner with RDIF to manufacture the Sputnik vaccine. We hope to make millions of doses in the coming months with trial batches starting in the month of September," said Serum Institute chief Adar Poonawalla. "With high efficacy and a good safety profile, it is critical that the Sputnik vaccine is accessible in full measure for people across India and the world. Given the uncertainty of the virus, it is important for international institutes, and governments to collaborate and further bolster up our fight against the pandemic," he added.
Source -NDTV
If you like the story and if you wish more such stories, support our effort Make a donation.

Tue Apr 07 2026 | By Newsdesk

Mon Apr 06 2026 | By Newsdesk

Mon Apr 06 2026 | By Newsdesk

Mon Apr 06 2026 | By Newsdesk

Mon Apr 06 2026 | By Newsdesk